Pindolol — Membership Pricing

Other medications in Heart & Cardiovascular

• Pitavastatin
• Pravastatin
• Propafenone
• Quinapril
• Ramipril
• Ranolazine
• Riociguat
• Rivaroxaban

What Pindolol is approved for (FDA label)

Pindolol tablets are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.

Source: Read the full FDA label on DailyMed. Label effective date: July 17, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Pindolol (FDA label)

Most adverse reactions have been mild. The incidences listed in the following table are derived from 12-week comparative double-blind, parallel design trials in hypertensive patients given pindolol as monotherapy, given various active control drugs as monotherapy, or given placebo. Data for pindolol and the positive controls were pooled from several trials because no striking differences were seen in the individual studies, with one exception. When considering all adverse reactions reported, the frequency of edema was noticeably higher in positive control trials (16% pindolol vs. 9% positive control) than in placebo controlled trials (6% pindolol vs. 3% placebo).

Source: FDA prescribing information (DailyMed). Set ID: 0daed7b3-6017-4611-8c3a-2f390470f8bc. SPL document ID: 56d4c9d3-60e5-d3b6-e063-6294a90a8a04. Label effective date: July 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Pindolol (FDA label)

Pindolol tablets are contraindicated in: 1) bronchial asthma; 2) overt cardiac failure; 3) cardiogenic shock; 4) second and third degree heart block; 5) severe bradycardia. (See WARNINGS. )

Source: FDA prescribing information (DailyMed). Set ID: 0daed7b3-6017-4611-8c3a-2f390470f8bc. SPL document ID: 56d4c9d3-60e5-d3b6-e063-6294a90a8a04. Label effective date: July 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Pindolol (FDA label)

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients receiving pindolol plus a catecholamine-depleting agent should, therefore, be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension. Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. Pindolol has been shown to increase serum thioridazine levels when both drugs are coadministered. Pindolol levels may also be increased with this combination. Risk of Anaphylactic Reaction While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.

Source: FDA prescribing information (DailyMed). Set ID: 0daed7b3-6017-4611-8c3a-2f390470f8bc. SPL document ID: 56d4c9d3-60e5-d3b6-e063-6294a90a8a04. Label effective date: July 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.